(3) Including ENOVIA Life Sciences Compliance and Quality Management (Q1 2019: €3.3m)
(4) Variation compared to the same period in the prior year
DASSAULT SYSTEMES
CONDENSED CONSOLIDATED BALANCE SHEETS (IFRS)
(unaudited; in millions of Euros)
|
In millions of Euros |
IFRS reported |
|
|
March 31, |
December 31, |
|
|
2020 |
2019 |
|
|
ASSETS |
|
|
|
Cash and cash equivalents |
2,243.5 |
1,944.9 |
|
Accounts receivable, net |
1,111.6 |
1,319.2 |
|
Contract assets |
30.1 |
26.9 |
|
Other current assets |
337.3 |
378.0 |
|
Total current assets |
3,722.5 |
3,669.0 |
|
Property and equipment, net |
949.7 |
899.7 |
|
Goodwill and Intangible assets, net |
8,991.4 |
8,917.0 |
|
Other non-current assets |
393.6 |
386.9 |
|
Total non-current assets |
10,334.8 |
10,203.7 |
|
Total Assets |
€ 14,057.3 |
€ 13,872.6 |
|
LIABILITIES AND EQUITY |
|
|
|
Accounts payable |
166.2 |
220.0 |
|
Contract liabilities |
1,184.4 |
1,093.5 |
|
Borrowings, current |
7.0 |
4.4 |
|
Other current liabilities |
721.0 |
816.0 |
|
Total current liabilities |
2,078.6 |
2,133.8 |
|
Borrowings, non-current |
4,609.7 |
4,596.8 |
|
Other non-current liabilities |
1,902.0 |
1,879.4 |
|
Total non-current liabilities |
6,511.7 |
6,476.2 |
|
Non-controlling interests |
52.1 |
53.9 |
|
Parent shareholders' equity |
5,414.9 |
5,208.7 |
|
Total Liabilities and equity |
€ 14,057.3 |
€ 13,872.6 |
DASSAULT SYSTEMES
CONDENSED CONSOLIDATED CASH FLOW STATEMENTS (IFRS)
(unaudited; in millions of Euros)
|
In millions of Euros |
IFRS reported |
||
|
Three months ended |
|||
|
March 31, 2020 |
March 31, 2019 |
Change |
|
|
Net income attributable to equity holders of the parent |
112.4 |
160.8 |
(48.4) |
|
Non-controlling interest |
(3.2) |
(2.8) |
(0.4) |
|
Net income |
109.2 |
158.0 |
(48.8) |
|
Depreciation of property and equipment |
48.9 |
31.7 |
17.2 |
|
Amortization of intangible assets |
112.8 |
52.3 |
60.5 |
|
Adjustments for other non-cash items |
49.8 |
28.4 |
21.4 |
|
Changes in working capital |
137.4 |
218.1 |
(80.7) |
|
Net Cash Provided by (Used in) Operating Activities |
€ 458.1 |
€ 488.5 |
€ (30.5) |
|
Additions to property, equipment and intangibles |
(60.3) |
(25.1) |
(35.2) |
|
Payment for acquisition of businesses, net of cash acquired |
- |
(400.6) |
400.6 |
|
Other |
1.8 |
(3.0) |
4.8 |
|
Net Cash Provided by (Used in) Investing Activities |
€ (58.4) |
€ (428.7) |
€ 370.3 |
|
|
|
|
|
|
Proceeds from exercise of stock options |
23.7 |
13.5 |
10.2 |
|
Repurchase and sale of treasury stock |
(108.1) |
8.6 |
(116.7) |
|
Proceeds from borrowings |
1.5 |
- |
1.5 |
|
Repayment of borrowings |
- |
(0.9) |
0.9 |
|
Repayment of lease liabilities |
(25.5) |
(17.0) |
(8.5) |
|
Net Cash Provided by (Used in) Financing Activities |
€ (108.5) |
€ 4.2 |
€ (112.7) |
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
7.4 |
22.7 |
(15.3) |
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents |
€ 298.6 |
€ 86.7 |
€ 211.9 |
|
|
|
|
|
|
Cash and cash equivalents at beginning of period |
€ 1,944.9 |
€ 2,809.3 |
|
|
Cash and cash equivalents at end of period |
€ 2,243.5 |
€ 2,896.0 |
|
